Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x100px

Document › Details

Uniqure N.V.. (3/29/19). "Press Release: Uniqure to Participate in Multiple Upcoming Industry Conferences". Lexington, MA & Amsterdam.

	Organisation	Uniqure N.V. (Nasdaq: QURE)
	Group	Uniqure (Group)
	Organisation 2	Stifel (Group)
	Today	Stifel Financial Corporation (NYSE: SF)
	Product	H.C. Wainwright Global Life Sciences Conference 2019 London
	Product 2	Kempen Life Sciences Conference 2019 Amsterdam
	Index term	Uniqure–HC Wainwright: investor conference, 201904 supply service Uniqure attends HC Wainwright Global Life Sciences Conference in London
	Index term 2	Uniqure–Van Lanschot: investor conference, 201904 supply service Uniqure attends Kempen Life Sciences Conference 2019 in Amsterdam
	Person	Kapusta, Matthew (Matt) (Uniqure 201612– CEO before interim CEO before CFO before AngioDynamics + Smith & Nephew)
	Person 2	van Deventer, Sander (VectorY 202211– CEO + Co-Founder before CTO also Co-Founder of Forbion)

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in April:

> Stifel First Annual CNS Day in Boston, Mass.
Matt Kapusta, chief executive officer at uniQure, will participate in a panel discussion, “Gene Therapy Strategies in CNS,” on Monday, April 1 at 10:00 a.m. ET.

> Guggenheim Rare Disease & Gene Therapy Day in Boston, Mass.
Matt Kapusta will attend and participate in one-on-one investor meetings throughout the day on Tuesday, April 2.

> H.C. Wainwright Global Life Sciences Conference in London, England
Sander van Deventer, M.D., Ph.D., chief scientific officer at uniQure, will attend and participate in one-on-one investor meetings on Tuesday, April 9.

> EASL International Liver Congress in Vienna, Austria
Valerie Sier-Ferreira, Ph.D., principal scientist of immunology research at uniQure, will present “Lipid nanoparticle pre-treatment improves adeno-associated virus diffusion in the primate liver and enables an increase of therapeutic transgene expression” on Thursday, April 11 at 10:00 a.m. CET.
Anna Majowicz, Ph.D., scientist at uniQure, will present “Adeno-associated virus-serotype-specific transduction patterns in mice and non-human primates liver tissue: Implications for therapeutic efficacy” on April 11 at the 10:00 a.m. CET poster session.

> Kempen Life Science Conference in Amsterdam, the Netherlands
Sander van Deventer will attend and participate in investor one-on-one meetings on Tuesday, April 16.

> Alliance for Regenerative Medicine (ARM) Meeting on the Med in Barcelona, Spain
Jonathan Garen, chief business officer at uniQure, will present a corporate update on Tuesday, April 23 at 11:15 a.m. CET.

> American Society of Gene and Cell Therapy (ASGCT) 21st Annual Meeting in Washington, D.C.
uniQure will deliver multiple data presentations at the meeting, which takes place Monday, April 29 through Thursday, May 2. Specific details to follow when the meeting abstracts are released.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases. www.uniQure.com

uniQure Contacts

For Investors:

Maria E. Cantor Eva M. Mulder
Direct: 339-970-7536 Direct: +31 20 240 6103

For Media:

Tom Malone
Direct: 339-970-7558

Record changed: 2023-06-05